{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-23-000048","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.719937+00:00","generated_at":"2026-06-12T03:57:04.652491+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AnaptysBio Q2 net loss $39.8M; imsidolimab Phase 3 enrollment complete","bullets":["Q2 net loss $39.8M ($1.50/sh) vs $32.6M ($1.15) YoY; six-month loss $84.1M ($3.08/sh).","Completed enrollment of GEMINI-1 Phase 3 for imsidolimab in GPP; top-line data expected Q4 2023.","Cash and investments $488.7M at June 30; updated year-end 2023 guidance $380-395M; runway through 2026.","Initiating global Phase 2b for rosnilimab in RA in Q3 2023; second Phase 2 trial by year-end.","Daniel Faga appointed permanent president and CEO; new SAB members added."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-23-000048","json":"https://secwatch.observer/filing/0001370053-23-000048.json","markdown":"https://secwatch.observer/filing/0001370053-23-000048.md","text":"https://secwatch.observer/filing/0001370053-23-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000048/0001370053-23-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000048/anab-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:57:04.652491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ff66e90fc7393a4cde890ec69dbb4d8c18ac651","claim":"ANAPTYSBIO, INC reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 7, 2023, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000048/0001370053-23-000048-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}